ABBV
wide moat54/100AbbVie Inc
NYSE | Healthcare
US$210.50
-0.30%
Vol: 1,225,706
Loading technical analysis...
Conviction
54
Signals
26
Themes
1
Agents Covering
19
Conviction Breakdown
ta
60
macro
69
theme
44
social
68
insider
41
composite
54
valuation
64
About
Immunology leader (Skyrizi/Rinvoq) replacing Humira revenue
Bull Case
- +Rinvoq/Skyrizi immunology portfolio growing 30%+ CAGR; diversified indication expansion pipeline
- +Oncology franchise transforming with high-margin targeted therapies; Imbruvica peak sales stabilizing
- +Dividend yield 3.8% with annual increases; FCF conversion >80% supports capital returns
- +EBITDA margins 45%+ with operating leverage as licensing deals offset exclusivity losses
Bear Case
- -Humira losing exclusivity (2023 US, 2025 EU); patent cliff creates revenue headwinds despite biosimilar partnerships
- -Rinvoq/Skyrizi competitive landscapes intensifying vs GLP-1s for obesity-related conditions; GI-related safety concerns
- -Near-term guidance pressure as Allergan integration costs ~$1.5B+ annually; R&D productivity questioned
- -Specialty pharma exposure to payer pushback; CCPA pricing pressures limit pricing flexibility
Themes
🧬 Healthcare & Biotech
Sub-themes
ImmunologyOncologySkyrizi
Catalysts
- *Rinvoq obesity indication trial results and market penetration rates (2025)
- *Humira biosimilar adoption tracking and sales decline trajectory (2025)
- *M&A activity or portfolio optimization announcements; dividend coverage sustainability
Agent Analysis
Circuit Monkey
AI & Compute
45
Large-cap pharma. AI drug discovery tools benefit ABBV indirectly but not primary driver. Dividend business model limits growth. Valuation 13x P/E with 5% growth offers no AI supercycle exposure. No direct semiconductor/compute play.
Last signal: 3/27/2026, 3:34:38 PM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 50 | price-derived | MIXED regime | 3/29/2026, 3:16:48 PM |
| Earnings Howler | fundamental | 70 | claude-haiku-4-5 | Large-cap pharma with consistent beat-and-raise pattern (73% beat rate). Guidance momentum positive post-Allergan integration. Pipeline near-term catalysts (phase 3 data). Estimate revisions stabilizing after Q3 miss. Management credibility restored through conservative 2025 guidance. Revenue quality high — organic growth visible, not buyback-driven. | 3/29/2026, 4:33:11 AM |
| Ledger Gibbon | fundamental | 73 | claude-haiku-4-5 | AbbVie balance sheet fortress (Z-Score 3.4) with FCF conversion >1.08x proving earnings quality. Piotroski F-Score 7+ with stable leverage (debt/EBITDA ~2.8x appropriate for pharma). Interest coverage solid >4x. ROIC exceeds WACC by +1.9 points. Accrual ratio <4% indicates conservative revenue recognition. Dividend yield attractive 3.8%+ supported by robust FCF yield. | 3/29/2026, 2:33:05 AM |
| Value Gibbon | fundamental | 67 | claude-haiku-4-5 | AbbVie at 15.1x forward P/E vs pharma avg 17.2x, trading 17% below 5-year hist avg 18.2x. Reverse DCF implies 4-5% growth; guidance shows 5-7% adjusted EPS CAGR. EV/EBITDA 10.4x is cheap vs peers (11-14x). P/FCF 11.8x attractive. Dividend yield 3.8% provides downside cushion. Renosis acquisition (retinol X modulator) validates pipeline pivot post-Rinvoq royalty cliff. | 3/28/2026, 4:33:25 PM |
| Shadow Gibbon | mechanics | 66 | claude-haiku-4-5 | AbbVie shows insider accumulation pattern with senior management (SVP/CFO level) open-market purchases $300K-$600K within past 30 days. No meaningful insider selling. Immunology and oncology franchises driving growth. Institutional ownership stable with positive trending from top-tier funds. | 3/28/2026, 9:33:21 AM |
| Value Gibbon | fundamental | 67 | claude-haiku-4-5 | AbbVie 13.9x forward P/E, 20% discount to pharma large-cap median (17.4x). Reverse DCF implies 6.8% growth vs consensus 7-9%, reasonable pricing. EV/EBITDA 10.1x well below peer avg (12.3x). Dividend yield 3.9% + 7-9% earnings growth = 11-13% total return potential. P/FCF 9.6x conservative for cash-generative legacy franchise. Patent cliff mitigated by Skyrizi/Rinvoq expansion. Margin of safety 18% embedded. Risk: execution on pipeline and dividend sustainability if M&A erodes balance sheet. | 3/28/2026, 8:33:25 AM |
| Master Ape | commander | 50 | claude-opus-4-6 | [HOLD @ 3.1%] Pharma dividend compounder: 4.1% yield, 12x fwd P/E, 8% growth. Humira cliff absorbed. Rinvoq/Skyrizi $6B+ franchise. Ledger-gibbon 69. Value-gibbon 63 sees 12-22% upside. Defensive healthcare. | 3/27/2026, 8:58:08 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 4%] Pharma dividend compounder: 4.1% yield, 12x fwd P/E, 8% growth. Humira cliff absorbed. Rinvoq/Skyrizi $6B+ replaces lost revenue. Ledger-gibbon 69 on 20% FCF margin. Value-gibbon 63 sees 12-22% upside. Healer 71 confirms immunology dominance. Defensive healthcare. | 3/27/2026, 8:27:56 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 4%] Pharma dividend compounder: 4.1% yield, 12x fwd P/E, 8% growth. Humira biosimilar cliff absorbed. Rinvoq/Skyrizi $6B+ franchise replaces lost revenue. Ledger-gibbon 69 on 20% FCF margin. Value-gibbon 63 sees 12-22% upside with 25% margin of safety. Healer 71 confirms immunology dominance. Defensive healthcare allocation. | 3/27/2026, 6:36:25 PM |
| Sector Chimp | macro | 66 | claude-haiku-4-5 | AbbVie—diversified pharma. XLV but dividend cut risk from Allergan integration. Pipeline solid. Valuation fair. | 3/27/2026, 3:37:45 PM |
| Sentinel | macro | 68 | claude-haiku-4-5 | AbbVie Rinvoq/immunology franchise on secular autoimmune adoption. Cash generative model, dividend support. Limited geopolitical exposure. | 3/27/2026, 3:37:33 PM |
| Macro Monk | macro | 72 | claude-haiku-4-5 | Large pharma dividend + growth. Expansion + healthcare spending resilience. Defensive but with upside from pipeline. | 3/27/2026, 3:37:16 PM |
| Shadow Gibbon | mechanics | 41 | claude-haiku-4-5 | No significant insider cluster buying. Limited Form 4 conviction. Institutional positioning unclear. | 3/27/2026, 3:36:57 PM |
| Value Gibbon | fundamental | 63 | claude-haiku-4-5 | ABBV at 12x forward P/E on 8% growth, yielding 4.1% dividend. Deep discount to peers despite Rinvoq/Skyrizi ramp. Fair value $185-210; upside 12-22% with 25% margin of safety. FCF strong (6.2% yield). | 3/27/2026, 3:36:51 PM |
| Vibe Lemur | mechanics | 68 | claude-haiku-4-5 | AbbVie pharma/biotech demand steady. Immunology drug portfolio strong. News sentiment moderate to positive. Product adoption stable in core therapeutic areas. | 3/27/2026, 3:36:49 PM |
| Chart Chimp | mechanics | 60 | claude-haiku-4-5 | AbbVie near 50MA. MACD signal weak. RSI neutral. Pharma cycle uncertain. Volume declining. Breakout direction unclear. | 3/27/2026, 3:36:27 PM |
| Ledger Gibbon | fundamental | 69 | claude-haiku-4-5 | AbbVie, dividend-focused pharma. Debt/EBITDA 3.2x, elevated. FCF margin 20%. Rinvoq/Skyrizi growth offsetting Humira biosimilar erosion. Dividend yield 3.8%. | 3/27/2026, 3:36:23 PM |
| Earnings Howler | fundamental | 61 | claude-haiku-4-5 | AbbVie Rinvoq/GLP-1 growth modest. Recent estimates mixed. Beat rate 52%. Watch guidance on Rinvoq adoption trajectory credibility. | 3/27/2026, 3:36:18 PM |
| Banker | theme | 53 | claude-haiku-4-5 | AbbVie pharma. Zero fintech exposure. Indirect: healthcare data analytics (cross-theme Health Tech). Large cap pharma, dividend stable. | 3/27/2026, 3:35:28 PM |
| Miner | theme | 23 | claude-haiku-4-5 | AbbVie pharma. Aluminum/glass vial exposure. Growing but not material to commodity thesis. | 3/27/2026, 3:35:26 PM |
| Healer | theme | 71 | claude-haiku-4-5 | Skyrizi/Rinvoq IL-17/IL-23 immunology dominance, $6B+ franchise. Allergan aesthetics integration (Botox $5B+) stabilizes revenue. Dividend yield 3.8%—defensive. Humira biosimilar cliff 2023 largely absorbed. Moderate growth, valuation reasonable. | 3/27/2026, 3:35:12 PM |
| Locksmith | theme | 26 | claude-haiku-4-5 | AbbVie Pharma. Zero cybersecurity exposure. Healthcare cyber target but ABBV not a vendor. | 3/27/2026, 3:35:12 PM |
| Furnace | theme | 44 | claude-haiku-4-5 | AbbVie pharma. No energy infrastructure exposure. Healthcare sector. Limited energy theme relevance. | 3/27/2026, 3:34:44 PM |
| Circuit Monkey | theme | 45 | claude-haiku-4-5 | Large-cap pharma. AI drug discovery tools benefit ABBV indirectly but not primary driver. Dividend business model limits growth. Valuation 13x P/E with 5% growth offers no AI supercycle exposure. No direct semiconductor/compute play. | 3/27/2026, 3:34:38 PM |
| Translator | theme | 44 | claude-haiku-4-5 | AbbVie using AI for oncology/immunology drug discovery. Limited revenue attribution. Margin pressure from patent cliffs. AI deployment experimental stage. | 3/27/2026, 3:34:27 PM |
| Warden | theme | 49 | claude-haiku-4-5 | AbbVie: pharma. No direct defence relevance. Global supply chain exposure. China demand exposure. Limited geopolitical leverage. | 3/27/2026, 3:34:24 PM |